BioPharma Bitez: Roche, Voyage, UK Biotechs and more!

Welcome back everybody to another edition of “BioPharma Bitez” the top news in the industry as well as one story outside of it.

So, kicking things off in the past week, UK Biotechs had a record year of vesting with over 1.1 billion pounds which is about 1.44 billion dollars vested last year.

Voyager has scored a 1.8 billion dollar gene therapy packed with “neurocrine this past week as well.

Roche is pulling a phase three Alzheimer’s drug candidate after data shows that it did not approve above the baseline and as follows many other Alzheimer drug candidates recently have been pulled from clinical trials.

Moderna has moved it mRNA drug candidate into phase one clinical trials this week after promising rodent data showed its potential use in humans.

Calico has brought an abjad bet Aarif Khakoo to head development of the anti-aging pipeline that they have.

Now transitioning into the fun fact of the week. So, this past week, scientists have discovered a new, tiny “dwarf galaxy” that is believed to be the most isolated galaxy found yet to date. They’re calling it the “Bedin 1” after the scientists have discovered it.

The hot job of the week is the same as last week, I am still working on this regulatory buildout, many different roles. Whether it be on the CMC or strategy side. So, anybody that is in regulatory that may be of interest with an oncology company, it’s really rising and building out this new department. Feel free to reach out to me. My number is included at the beginning of this video and feel free to add me on LinkedIn.

So, share this everywhere. I really appreciate everyone’s time this week. I look forward to seeing you all next week for another edition of “BioPharma Bitez.”